Merck & Co. Announces Positive Results From Phase 2 CADENCE Study, Reducing Pulmonary Vascular Resistance in Adults with Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction.

Merck & Co. (MRK) announced detailed results from the Phase 2 CADENCE study, showing a statistically significant and clinically meaningful reduction in pulmonary vascular resistance with WINREVAIR compared to placebo at week 24. The study evaluated the efficacy, safety, and tolerability of two doses of WINREVAIR in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction.